Gilead pays Watertown startup Lyndra $123M to develop longer-lasting HIV pill

HIV patients could one day replace a daily pill for one that would last a week or more, should a new drug development deal struck this week prove successful. California-based Gilead Sciences Inc. (Nasdaq: GILD) is enlisting Watertown startup Lyndra Therapeutics to develop one or more HIV drugs that could last a week, allowing patients to take fewer pills. Gilead will pay Lyndra up to $122.5 million in R&D milestones, as well as commercial royalties on any products produced through the deal. Lyndra…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news